Key questions in metastasis: new insights in molecular pathways and therapeutic implications

G Gueron1, A De Siervi, E Vazquez

  • 1Department of Biological Chemistry, School of Sciences, University of Buenos Aires, Ciudad Universitaria, Pabellon II, 2do Piso (1428), Buenos Aires, Argentina-CONICET.

Insights

Understanding cancer metastasis, a major challenge in therapy, requires examining gene expression and inflammatory factors. Novel approaches like nanoparticle imaging and bioinformatics offer new diagnostic and therapeutic strategies for metastatic disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Metastasis formation involves complex, rate-limiting steps, including cell motility, invasiveness, and survival in distant organs.
  • Metastasis initiation and progression genes have distinct yet overlapping roles, influencing both primary tumor growth and distant colonization.
  • Current clinical therapeutics face significant challenges in treating metastatic disease effectively.

Purpose of the Study:

  • To review novel gene signatures associated with metastasis.
  • To explore the role of inflammatory factors, cell plasticity, and microRNAs in metastasis.
  • To assess emerging theranostic platforms and bioinformatic tools for cancer diagnostics and treatment.

Main Methods:

  • Review of recent literature on gene signatures in metastases.
  • Analysis of inflammatory factors, cell plasticity, and microRNA roles in metastasis.
  • Evaluation of nanoparticle imaging and bioinformatic analysis of metastasis-related proteins.

Main Results:

  • Identification of novel gene signatures in metastatic tissues.
  • Mechanistic insights into inflammatory factors, cell plasticity, and microRNAs driving metastasis.
  • Progress in nanoparticle-based theranostics and bioinformatic analysis of metastatic niches.

Conclusions:

  • Understanding molecular mechanisms of tumor dissemination is crucial for clinical translation.
  • Emerging tools like gene signatures, theranostics, and bioinformatics offer promising avenues for cancer therapy.
  • Targeting metastasis initiation and progression pathways can improve treatment outcomes and surgical procedures.

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...